ClinicalTrials.gov
ClinicalTrials.gov Menu

Mediterranean Diet and Protein-Sparing Modified Diet for Metabolic Syndrome in Liver Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02174783
Recruitment Status : Terminated
First Posted : June 26, 2014
Last Update Posted : March 14, 2017
Sponsor:
Information provided by (Responsible Party):
The Cleveland Clinic

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Many metabolic complications can develop after liver transplant including: diabetes, high blood pressure, obesity, heart attacks and stroke. The goal of this study is to look at the safety and effect of 2 well known and established diet regimens on the people who had a prior liver transplant and investigate whether it helps with the control of these comorbidities.

Condition or disease Intervention/treatment Phase
Liver Transplantation Metabolic Syndrome X Obesity Other: Control group Other: Mediterranean diet Other: Protein-Sparing Modified Fast (PSMF) Not Applicable

Detailed Description:
The Mediterranean diet has been shown to be effective in improving hepatic steatosis, insulin sensitivity, diabetes control and reducing cardiovascular risk in adult patients, but there is no data available for patients who underwent liver transplant. The protein-sparing modified fast (PSMF) diet has been used for years at the Cleveland Clinic to treat adult patients with obesity-related medical problems, but its safety and efficacy has not been established in liver transplant recipients.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Safety and Efficacy of Mediterranean Diet and Protein-Sparing Modified Diet on Obesity and Metabolic Syndrome in Liver Transplant Recipients: A Randomized Clinical Trial
Study Start Date : June 2014
Actual Primary Completion Date : January 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Control group
Standard of care group
 Other: Control group
Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral.
Experimental: Mediterranean diet
Mediterranean diet for 6 months
 Other: Mediterranean diet
Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet.
Experimental: Protein-Sparing Modified Fast (PSMF)
PSMF for 6 months
 Other: Protein-Sparing Modified Fast (PSMF)

Patient will be referred to the dietitian for an appointment to discuss the PSMF plan.

Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight.

Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Weight loss [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Number of Participants with Serious and Non-Serious Adverse Events [ Time Frame: 6 months ]
    Investigate the safety of the mediterranean diet and PSMF in post liver transplant patients

  2. Change in Hb A1c compared to baseline [ Time Frame: 6 months ]
  3. Change in HDL and LDL compared to baseline [ Time Frame: 6 months ]
  4. Change in triglyceride compared to baseline [ Time Frame: 6 months ]
  5. Change in blood pressure compared to baseline [ Time Frame: 6 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Adult patients > 18 years old who had a successful liver transplant at least 1 year prior to enrollment who also have a BMI>30 with previous failed attempts at weight loss via conventional methods. In addition to one of the following:

  1. Triglyceride (TG)>150 mg/dl or specific treatment for this lipid abnormality
  2. HDL <40 mg/dl in females and <50 mg/dl in males or specific treatment of this lipid abnormality
  3. Systolic BP >130 or diastolic BP >85 mm Hg or treatment for previously diagnosed hypertension
  4. Fasting plasma glucose >100 mg/dl or previously diagnosed type 12 diabetes

Exclusion Criteria:

  • Significant behavioral issues that would interfere with compliance
  • Lack of readiness to change (pre-contemplation, contemplation or preparation stages)
  • Previous bariatric surgery
  • Pregnant or planning to become pregnant
  • History of a documented eating disorder (e.g. bulimia)
  • History of kidney stones
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02174783


Locations
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Sponsors and Collaborators
The Cleveland Clinic
Investigators
Principal Investigator: mohammed Eyad Yaseen Alsabbagh, MD The Cleveland Clinic
Study Director: Naim Alkhouri, MD The Cleveland Clinic
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party: The Cleveland Clinic
ClinicalTrials.gov Identifier: NCT02174783     History of Changes
Other Study ID Numbers: PTMS-9500
First Posted: June 26, 2014    Key Record Dates
Last Update Posted: March 14, 2017
Last Verified: July 2014

Keywords provided by The Cleveland Clinic:
Weight Loss
Diet, Mediterranean
Diet, Reducing
protein sparing modified diet

Additional relevant MeSH terms:
Syndrome
Obesity
Metabolic Syndrome X
Disease
Pathologic Processes
Overnutrition
Nutrition Disorders
 Overweight
Body Weight
Signs and Symptoms
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases